Long-Running Study Identifies Modifiable Dementia Risk Factor in Older Adults
October 22, 2018
Pittsburgh, PA, USA – For older adults, it may seem as though the die is already cast regarding their odds of developing dementia, but new research from the University of Pittsburgh has identified a dementia risk factor among older adults that should be modifiable even well into old age.
The study, which draws on data collected from following hundreds of elderly Pittsburghers for more than 15 years, has been published in the Journal of Alzheimer’s Disease. The main finding is that arterial stiffness is a good proxy for predicting who will go on to develop dementia. Even minor signs of brain disease were not as telling. Since arterial stiffness can be reduced by antihypertensive drugs, and likely also lifestyle interventions, these findings suggest that at-risk patients may have the power to prevent or delay the onset of dementia.
“As the large arteries get stiffer, their ability to cushion the pumping of blood from the heart is diminished, and that transmits increased pulsing force to the brain, which contributes to silent brain damage that increases dementia risk,” said senior author Rachel Mackey, PhD, MPH (pictured), assistant professor of epidemiology, University of Pittsburgh Graduate School of Public Health. “Although arterial stiffness is associated with markers of silent, or subclinical, brain damage and cognitive decline, until now, it was not clear that arterial stiffness was associated with the risk of dementia.”
The authors analyzed the association between arterial stiffness and dementia among 356 older adults, with an average age of 78, who were part of the Cardiovascular Health Study Cognition Study (CHS-CS), a long-term study to identify dementia risk factors. This study is unusual because it had 15 years of almost complete follow-up of cognitive status and outcomes for older participants.
All participants included in the present study were dementia-free when the study started in 1998. During this same period, Mackey and her team tested their aortic stiffness with pulse wave velocity (PWV), a noninvasive measure of the speed at which the blood pressure pulse travels through the arteries. Study participants also had MRI scans of their brains to measure signs of subclinical brain disease.
The researchers found that subjects with high PWV readings were 60 percent more likely to develop dementia during the following 15 years compared to those with lower PWV values. Although arterial stiffness is correlated with subclinical brain disease and risk factors for cardiovascular disease, these confounding variables did not explain the results.
“It’s very surprising that adjusting for subclinical brain disease markers didn’t reduce the association between arterial stiffness and dementia at all,” said Chendi Cui, MS, first author on the paper and doctoral student at Pitt Public Health. “We expect that arterial stiffness increases the risk of dementia partly by increasing subclinical brain damage. However, in these older adults, arterial stiffness and subclinical brain damage markers appeared to be independently related to dementia risk.”
That’s promising because there isn’t much evidence that it’s possible to reverse subclinical brain disease, whereas arterial stiffening can be reduced by antihypertensive medication and perhaps also healthy lifestyle changes such as exercise. For example, this study showed that exercise at an average age of 73 was associated with lower PWV five years later. So, if elderly patients get flagged with a high PWV reading or marker of subclinical brain damage, they may still have the chance to stave off dementia.
“What’s exciting to think about is that the strong association of arterial stiffness to dementia in old age suggests that even at age 70 or 80, we might still be able to delay or prevent the onset of dementia,” Mackey said.
Additional authors on this study include Akira Sekikawa, M.D., Ph.D., M.P.H., Lewis Kuller, M.D., Dr.P.H., Oscar Lopez, M.D., Anne Newman, M.D., M.P.H., and Allison Kuipers, Ph.D., all of Pitt. Drs. Lopez and Kuller directed the CHS-CS study. Pitt’s Ultrasound Research Laboratory enabled the PWV measurements.
This research was supported by contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01-HC55222, N01-HC85079, N01-HC85080, R01-HL64587, and grants U01-HL080295 and U01-L130114 from the National Heart, Lung, and Blood Institute with additional contribution from the National Institute of Neurological Disorders and Stroke. The National Institute on Aging provided additional support through grants R01-AG15928, R01-AG023629, R01-AG023629 and RF1-AG051615.
NOTES FOR EDITORS
Full study: C Cui, A Sekikawa, LH Kuller, OL Lopez, AB Newman, AL Kuipers, RH Mackey (2018) “Aortic Stiffness is Associated with Increased Risk of Incident Dementia in Older Adults” J Alzheimers Dis 66 (1) (doi: 10.3233/JAD-180449).
About the University of Pittsburgh Schools of the Health Sciences
The University of Pittsburgh Schools of the Health Sciences include the schools of Medicine, Nursing, Dental Medicine, Pharmacy, Health and Rehabilitation Sciences and the Graduate School of Public Health. The schools serve as the academic partner to the UPMC (University of Pittsburgh Medical Center). Together, their combined mission is to train tomorrow’s health care specialists and biomedical scientists, engage in groundbreaking research that will advance understanding of the causes and treatments of disease and participate in the delivery of outstanding patient care. Since 1998, Pitt and its affiliated university faculty have ranked among the top 10 educational institutions in grant support from the National Institutes of Health. health.pitt.edu.
About the Journal of Alzheimer’s Disease
Celebrating its 20th anniversary in 2018, the Journal of Alzheimer’s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. JAD has an Impact Factor of 3.476 according to the 2017 Journal Citation Reports (Clarivate Analytics, 2018). j-alz.com